Drug Discovery: Executive Overview

Drug discovery is being reshaped by advances in molecular biology, computational chemistry, automation, high-throughput screening, and data science. The field now combines experimental and computational methods across target identification, hit discovery, lead optimization, biomarker development, and translational validation. Progress depends on integrating diverse evidence while managing reproducibility, safety, intellectual-property, and regulatory requirements.

How Drug Discovery Is Changing

The landscape is moving from sequential, laboratory-intensive workflows toward integrated platforms that connect biological data, simulation, screening, and decision support. Multi-omics, structure-based design, organoid and cell-based models, and automated experimentation are broadening the evidence available before clinical testing. At the same time, stricter expectations for data provenance, model validation, quality systems, and inclusive clinical translation are influencing how discovery programs are designed and governed.

Artificial Intelligence Across the Discovery Workflow

Artificial intelligence is being applied to target prioritization, protein-structure analysis, virtual screening, de novo molecular design, property prediction, synthesis planning, image analysis, and biomarker selection. Its practical value is greatest when models are trained on well-curated data and linked to experimentally testable hypotheses. Limitations remain, including dataset bias, weak generalization beyond training conditions, explainability challenges, and the need to confirm predictions through robust laboratory and clinical evidence.

Regional Differences in Drug Discovery Capabilities

North America combines deep biomedical research capacity, venture financing, advanced clinical infrastructure, and strong adoption of computational tools. Europe benefits from coordinated research networks, sophisticated regulatory science, and public-private collaboration, while Asia-Pacific is strengthened by expanding biotechnology ecosystems, manufacturing capabilities, and large patient and research populations. Latin America is developing translational and clinical capabilities unevenly across countries. The Middle East is increasing investment in research infrastructure and health innovation, and Africa is building discovery and clinical capacity while addressing funding, data, workforce, and laboratory-access constraints.

Drug Discovery Across Major International Groups

ASEAN economies are improving research connectivity, clinical-trial capabilities, and biomanufacturing links, though capacity varies substantially among members. BRICS countries span major scientific, industrial, and patient-population resources but face differences in regulation, infrastructure, and data interoperability. The European Union emphasizes collaborative research, harmonized regulation, and cross-border data frameworks. G7 members generally provide advanced research, capital, and regulatory environments. GCC states are strengthening health-technology infrastructure and scientific investment, while NATO members benefit from extensive biomedical and security-relevant research networks, with participation and capabilities differing across the alliance.

Country-Level Patterns in Drug Discovery

The United States and Canada pair strong academic research with advanced biotechnology and clinical ecosystems. Germany, France, Italy, Spain, and the United Kingdom contribute established pharmaceutical, university, translational, and regulatory capabilities within a connected European environment. China, Japan, South Korea, India, and Australia are expanding computational biology, advanced screening, biotechnology, and clinical research capacity through distinct national strategies. Brazil and Mexico are important Latin American research and clinical hubs, while Russia retains scientific and pharmaceutical capabilities amid differing access, collaboration, and regulatory conditions.

Priorities for Drug Discovery Leaders

Leaders should build interoperable data foundations with clear provenance, standardized metadata, and appropriate access controls. They should validate artificial-intelligence systems prospectively, pair predictions with orthogonal experiments, and monitor performance across disease areas and populations. Portfolio decisions should incorporate translational biomarkers, manufacturability, safety liabilities, and regulatory expectations early. Organizations can also improve resilience by developing multidisciplinary talent, strengthening external research partnerships, adopting reproducible laboratory practices, and maintaining governance for intellectual property, privacy, bias, and model accountability.

Research Methodology for the Executive Summary

This summary uses a structured synthesis of established drug-discovery practices, technology developments, regulatory considerations, and regional ecosystem characteristics. Findings are organized across workflow transformation, artificial-intelligence applications, geography, international groupings, and country-level capabilities. Claims are intentionally qualitative and avoid market estimates, forecasts, market shares, and company-specific assessments. Interpretation should be complemented by primary literature, regulatory publications, clinical-trial records, patent data, and locally validated expert evidence for operational decisions.

Conclusion: Building More Predictive Discovery Systems

Drug discovery is becoming more connected, data-intensive, and experimentally integrated. Artificial intelligence can accelerate prioritization and improve the use of complex biological evidence, but it does not replace rigorous validation or scientific judgment. Durable progress will depend on trustworthy data, reproducible experimentation, responsible governance, skilled teams, and regional collaboration that converts computational insight into clinically meaningful medicines.

Research report

1.Preface
1. 1.1Objectives of the Study
2. 1.2Market Definition
3. 1.3Market Segmentation & Coverage
4. 1.4Years Considered for the Study
5. 1.5Currency Considered for the Study
6. 1.6Language Considered for the Study
7. 1.7Key Stakeholders
2.Research Methodology
1. 2.1Introduction
2. 2.2Research Design
  1. 2.2.1Primary Research
  2. 2.2.2Secondary Research
3. 2.3Research Framework
  1. 2.3.1Qualitative Analysis
  2. 2.3.2Quantitative Analysis
4. 2.4Market Size Estimation
  1. 2.4.1Top-Down Approach
  2. 2.4.2Bottom-Up Approach
5. 2.5Data Triangulation
6. 2.6Research Outcomes
7. 2.7Research Assumptions
8. 2.8Research Limitations
3.Executive Summary
1. 3.1Introduction
2. 3.2CXO Perspective
3. 3.3New Revenue Opportunities
4. 3.4Next-Generation Business Models
5. 3.5Industry Roadmap
4.Market Overview
1. 4.1Introduction
2. 4.2Industry Ecosystem & Value Chain Analysis
  1. 4.2.1Supply-Side Analysis
  2. 4.2.2Demand-Side Analysis
  3. 4.2.3Stakeholder Analysis
3. 4.3Market Dynamics
  1. 4.3.1Key Drivers
  2. 4.3.2Key Restraints
  3. 4.3.3Key Opportunities
  4. 4.3.4Key Challenges
4. 4.4Porter’s Five Forces Analysis
5. 4.5PESTLE Analysis
6. 4.6Market Outlook
  1. 4.6.1Near-Term Market Outlook (0–2 Years)
  2. 4.6.2Medium-Term Market Outlook (3–5 Years)
  3. 4.6.3Long-Term Market Outlook (5–10 Years)
7. 4.7Go-to-Market Strategy
5.Market Insights
1. 5.1Consumer Insights & End-User Perspective
2. 5.2Consumer Experience Benchmarking
3. 5.3Opportunity Mapping
4. 5.4Distribution Channel Analysis
5. 5.5Pricing Trend Analysis
6. 5.6Regulatory Compliance & Standards Framework
7. 5.7ESG & Sustainability Analysis
8. 5.8Disruption & Risk Scenarios
9. 5.9Return on Investment & Cost-Benefit Analysis
6.Cumulative Impact of Artificial Intelligence 2026
7.Drug Discovery Market, by Offering
1. 7.1Introduction
2. 7.2Instruments & Automation
  1. 7.2.1High-Throughput Screening Systems
    1. 7.2.1.1Microplate Readers
    2. 7.2.1.2Time-Resolved Fluorescence Readers
    3. 7.2.1.3Fluorescence Polarization Readers
    4. 7.2.1.4AlphaScreen & AlphaLISA Detection Systems
    5. 7.2.1.5Automated Plate Washers
    6. 7.2.1.6Automated Plate Dispensers
    7. 7.2.1.7Automated Incubation Systems
    8. 7.2.1.8Automated Plate Handling Systems
    9. 7.2.1.9Colony Pickers
    10. 7.2.1.10Microplate Sealing & De-Sealing Systems
  2. 7.2.2Liquid Handling & Sample Preparation Automation Systems
    1. 7.2.2.1Automated Liquid Handling Systems
    2. 7.2.2.2Automated Pipetting Systems
    3. 7.2.2.3Automated Sample Preparation Systems
    4. 7.2.2.4Laboratory Scheduling & Workflow Systems
    5. 7.2.2.5Microplate Replicators
    6. 7.2.2.6Automated Compound Reformatting Systems
    7. 7.2.2.7Dispensing Systems
    8. 7.2.2.8Automated Dilution Systems
  3. 7.2.3High-Content Imaging & Phenotypic Screening Systems
    1. 7.2.3.1Confocal Imaging Systems
    2. 7.2.3.2Widefield Fluorescence Imaging Systems
    3. 7.2.3.3Live-Cell Imaging Systems & Label-Free Imaging Systems
    4. 7.2.3.4Automated Microscopy Platforms
    5. 7.2.3.5Image-Based Cytometry Systems
    6. 7.2.3.6Organoid & Three-Dimensional Culture Imaging Systems
    7. 7.2.3.7Phenotypic Profiling Systems
  4. 7.2.4Laboratory Robotics & Integrated Automation Systems
    1. 7.2.4.1Robotic Laboratory Arms
    2. 7.2.4.2Automated Workcells
  5. 7.2.5Analytical Chemistry Instruments
    1. 7.2.5.1Liquid Chromatography Systems
    2. 7.2.5.2Gas Chromatography Systems
    3. 7.2.5.3Liquid Chromatography-Mass Spectrometry Systems
    4. 7.2.5.4Tandem Mass Spectrometry Systems
    5. 7.2.5.5Capillary Electrophoresis Systems
    6. 7.2.5.6Preparative Chromatography Systems
    7. 7.2.5.7Elemental Analysis Systems
  6. 7.2.6Biophysical Characterization & Binding Analysis Instruments
    1. 7.2.6.1Surface Plasmon Resonance Systems
    2. 7.2.6.2Bio-Layer Interferometry Systems
    3. 7.2.6.3Isothermal Titration Calorimetry Systems
    4. 7.2.6.4Microscale Thermophoresis Systems
    5. 7.2.6.5Differential Scanning Fluorimetry Systems
    6. 7.2.6.6Quartz Crystal Microbalance Systems
    7. 7.2.6.7Label-Free Binding Analysis Systems
  7. 7.2.7Structural Biology Instruments
    1. 7.2.7.1X-Ray Crystallography Systems
    2. 7.2.7.2Protein Crystallization Screening Systems
    3. 7.2.7.3Cryo-Electron Microscopy Systems
    4. 7.2.7.4Cryo-EM Sample Preparation Systems
    5. 7.2.7.5Nuclear Magnetic Resonance Spectroscopy Systems
    6. 7.2.7.6Small-Angle X-Ray Scattering Systems
    7. 7.2.7.7Protein Crystallization Imaging Systems
    8. 7.2.7.8Hydrogen-Deuterium Exchange Mass Spectrometry Systems
  8. 7.2.8Cell Analysis And Single-Cell Analysis Instruments
    1. 7.2.8.1Flow Cytometers
    2. 7.2.8.2Cell Sorting Systems
    3. 7.2.8.3Single-Cell Analysis Platforms
    4. 7.2.8.4Automated Cell Counters
    5. 7.2.8.5Cell Viability Analyzers
    6. 7.2.8.6Cell Migration & Invasion Analysis Systems
    7. 7.2.8.7Cell Metabolism Analyzers
    8. 7.2.8.8Electrophysiology Screening Systems
  9. 7.2.9Genomics, Transcriptomics, Proteomics, & Multiomics Instruments
    1. 7.2.9.1Next-Generation Sequencing Systems
    2. 7.2.9.2Single-Cell Sequencing Platforms
    3. 7.2.9.3Spatial Biology Platforms
    4. 7.2.9.4PCR Systems
    5. 7.2.9.5Microarray Platforms
    6. 7.2.9.6Metabolomics Platforms
  10. 7.2.10In Vivo Pharmacology & Preclinical Research Instruments
    1. 7.2.10.1Micro-Computed Tomography Systems
    2. 7.2.10.2In Vivo Optical Imaging Systems
    3. 7.2.10.3Micro-Magnetic Resonance Imaging Systems
    4. 7.2.10.4Micro-Positron Emission Tomography Systems
    5. 7.2.10.5Telemetry Systems
    6. 7.2.10.6Metabolic Cage Systems
    7. 7.2.10.7Disease Monitoring Systems
    8. 7.2.10.8Small Animal Dosing & Sampling Systems
3. 7.3Reagents, Consumables, & Libraries
  1. 7.3.1Biochemical Reagents
  2. 7.3.2Chromatography Consumables
  3. 7.3.3Cell Lines & Disease Models;
  4. 7.3.4Antibody & Protein Reagents
  5. 7.3.5Microplates, Tips, & Lab Plastics
  6. 7.3.6Assay Kits
  7. 7.3.7Compound Libraries
4. 7.4Software
  1. 7.4.1Molecular Modeling & Simulation Software
  2. 7.4.2Lab Informatics & Workflow Orchestration
  3. 7.4.3AI & Machine Learning Platforms
  4. 7.4.4Bioinformatics & Multiomics Analytics
  5. 7.4.5Data Integration & Knowledge Graph Platforms
5. 7.5Services
  1. 7.5.1Target Identification & Validation Services
  2. 7.5.2Assay Development Services
  3. 7.5.3Screening Services
  4. 7.5.4Hit-To-Lead Services
  5. 7.5.5Lead Optimization Services
  6. 7.5.6Medicinal Chemistry Services
  7. 7.5.7DMPK Services
  8. 7.5.8Toxicology Services
  9. 7.5.9Structural Biology Services
8.Drug Discovery Market, by Drug Modality
1. 8.1Introduction
2. 8.2Small Molecules
  1. 8.2.1Conventional Small Molecules
  2. 8.2.2Targeted Protein Degraders
  3. 8.2.3Complex Small Molecules
3. 8.3Biologics
  1. 8.3.1Antibody-Based
  2. 8.3.2Protein-Based
  3. 8.3.3Peptide-Based
4. 8.4Nucleic Acid Therapies
  1. 8.4.1RNA-Based
  2. 8.4.2DNA-Based
  3. 8.4.3Gene Therapy Vectors
5. 8.5Cell Therapies
  1. 8.5.1Immune Cell Therapies
  2. 8.5.2Regenerative Cell Therapies
  3. 8.5.3Engineered Cell Therapies
9.Drug Discovery Market, by Therapeutic Area
1. 9.1Introduction
2. 9.2Cardiovascular
3. 9.3Metabolic
4. 9.4Immunology
5. 9.5Central Nervous System
6. 9.6Oncology
7. 9.7Infectious Diseases
8. 9.8Respiratory
9. 9.9Rare Diseases
10.Drug Discovery Market, by End User
1. 10.1Introduction
2. 10.2Pharmaceutical Companies
3. 10.3Biotechnology Companies
4. 10.4Academic & Research Institutes
5. 10.5Contract Research Organizations
11.Drug Discovery Market, by Region
1. 11.1Introduction
2. 11.2Asia-Pacific
3. 11.3Europe
4. 11.4North America
5. 11.5Latin America
6. 11.6Africa
7. 11.7Middle East
12.Drug Discovery Market, by Group
1. 12.1Introduction
2. 12.2NATO
3. 12.3G7
4. 12.4European Union
5. 12.5BRICS
6. 12.6ASEAN
7. 12.7GCC
13.Drug Discovery Market, by Country
1. 13.1Introduction
2. 13.2United States
3. 13.3China
4. 13.4Germany
5. 13.5Japan
6. 13.6India
7. 13.7Canada
8. 13.8United Kingdom
9. 13.9France
10. 13.10Brazil
11. 13.11Mexico
12. 13.12Australia
13. 13.13Italy
14. 13.14South Korea
15. 13.15Russia
16. 13.16Spain
14.Competitive Landscape
1. 14.1Market Share Analysis, 2025
2. 14.2Market Concentration Analysis, 2025
  1. 14.2.1Concentration Ratio (CR)
  2. 14.2.2Herfindahl Hirschman Index (HHI)
3. 14.3Recent Developments & Impact Analysis, 2025
4. 14.4Product Portfolio Analysis, 2025
5. 14.5Benchmarking Analysis, 2025
15.Company Profiles
1. 15.1Thermo Fisher Scientific Inc.
2. 15.2Charles River Laboratories International, Inc.
3. 15.3WuXi AppTec Co., Ltd.
4. 15.4Danaher Corporation
5. 15.5Eurofins Scientific SE
6. 15.6Agilent Technologies, Inc.
7. 15.7Merck KGaA
8. 15.8Pharmaron Beijing Co., Ltd.
9. 15.9Labcorp Holdings Inc.
10. 15.10Evotec SE
11. 15.11Avantor, Inc.
12. 15.12Waters Corporation
13. 15.13IQVIA Holdings Inc.
14. 15.14Revvity, Inc.
15. 15.15Bruker Corporation
16. 15.16Illumina, Inc.
17. 15.17Syngene International Limited
18. 15.18Sartorius AG
19. 15.19Bio-Rad Laboratories, Inc.
20. 15.20Aragen Life Sciences Limited
21. 15.21Corning Incorporated
22. 15.22Inotiv, Inc.
23. 15.23Curia Global, Inc.
24. 15.24Tecan Group Ltd.
25. 15.25Schrödinger, Inc.
26. 15.2610x Genomics, Inc.
27. 15.27Benchling, Inc.
28. 15.28XtalPi Holdings Limited
29. 15.29Certara, Inc.
30. 15.30Recursion Pharmaceuticals, Inc.
31. 15.31AbCellera Biologics Inc.
32. 15.32Absci Corporation
33. 15.33Adimab, LLC
34. 15.34Atomwise Inc.
35. 15.35BenevolentAI S.A.
36. 15.36ChemPartner Pharmatech Co., Ltd.
37. 15.37Collaborative Drug Discovery, Inc.
38. 15.38Crown Bioscience International
39. 15.39Dassault Systèmes SE
40. 15.40Domainex Limited
41. 15.41Dotmatics Limited
42. 15.42Generate Biomedicines, Inc.
43. 15.43Ginkgo Bioworks Holdings, Inc.
44. 15.44Iktos SAS
45. 15.45Insilico Medicine Cayman TopCo
46. 15.46Isomorphic Labs Limited
47. 15.47Jubilant Biosys Limited
48. 15.48Lonza Group AG
49. 15.49OmniAb, Inc.
50. 15.50Owkin, Inc.
51. 15.51Relay Therapeutics, Inc.
52. 15.52Sai Life Sciences Limited
53. 15.53Selvita S.A.
54. 15.54Shanghai Medicilon Inc.
55. 15.55Sygnature Discovery Limited
56. 15.56Taconic Biosciences, Inc.
57. 15.57TCG Lifesciences Private Limited
58. 15.58The Jackson Laboratory
59. 15.59Twist Bioscience Corporation
60. 15.60Viva Biotech Holdings
16.Key Experts

Drug Discovery

360iResearch introduction